^
    Back
    Association details:
    Biomarker:HER-2 exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug Class:HER2 exon 20 mutation inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Curr Oncol
    Title:

    Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer

    Published date:
    08/25/2023
    Excerpt:
    Overall survival was significantly better among HER2 ex20ins patients who received ex20ins-specific TKIs.
    DOI:
    10.3390/curroncol30080515